Literature DB >> 33186092

rpoB mutations conferring rifampicin-resistance affect growth, stress response and motility in Vibrio vulnificus.

Laura Cutugno1, Jennifer Mc Cafferty1, Jan Pané-Farré2,3, Conor O'Byrne1, Aoife Boyd1.   

Abstract

Rifampicin is a broad-spectrum antibiotic that binds to the bacterial RNA polymerase (RNAP), compromising DNA transcription. Rifampicin resistance is common in several microorganisms and it is typically caused by point mutations in the gene encoding the β subunit of RNA polymerase, rpoB. Different rpoB mutations are responsible for various levels of rifampicin resistance and for a range of secondary effects. rpoB mutations conferring rifampicin resistance have been shown to be responsible for severe effects on transcription, cell fitness, bacterial stress response and virulence. Such effects have never been investigated in the marine pathogen Vibrio vulnificus, even though rifampicin-resistant strains of V. vulnificus have been isolated previously. Moreover, spontaneous rifampicin-resistant strains of V. vulnificus have an important role in conjugation and mutagenesis protocols, with poor consideration of the effects of rpoB mutations. In this work, effects on growth, stress response and virulence of V. vulnificus were investigated using a set of nine spontaneous rifampicin-resistant derivatives of V. vulnificus CMCP6. Three different mutations (Q513K, S522L and H526Y) were identified with varying incidence rates. These three mutant types each showed high resistance to rifampicin [minimal inhibitory concentration (MIC) >800 µg ml-1], but different secondary effects. The strains carrying the mutation H526Y had a growth advantage in rich medium but had severely reduced salt stress tolerance in the presence of high NaCl concentrations as well as a significant reduction in ethanol stress resistance. Strains possessing the S522L mutation had reduced growth rate and overall biomass accumulation in rich medium. Furthermore, investigation of virulence characteristics demonstrated that all the rifampicin-resistant strains showed compromised motility when compared with the wild-type, but no major effects on exoenzyme production were observed. These findings reveal a wide range of secondary effects of rpoB mutations and indicate that rifampicin resistance is not an appropriate selectable marker for studies that aim to investigate phenotypic behaviour in this organism.

Entities:  

Keywords:  Vibrio vulnificus; motility; osmotolerance; rifampicin resistance; rpoB; stress response

Mesh:

Substances:

Year:  2020        PMID: 33186092      PMCID: PMC7819355          DOI: 10.1099/mic.0.000991

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  46 in total

Review 1.  Wound infections caused by Vibrio vulnificus and other marine bacteria.

Authors:  J D Oliver
Journal:  Epidemiol Infect       Date:  2005-06       Impact factor: 2.451

2.  Vibrio vulnificus rtxA1 gene recombination generates toxin variants with altered potency during intestinal infection.

Authors:  Jayme S Kwak; Hee-Gon Jeong; Karla J F Satchell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

3.  Characterization of the pleiotropic phenotypes of rifampin-resistant rpoB mutants of Escherichia coli.

Authors:  D J Jin; C A Gross
Journal:  J Bacteriol       Date:  1989-09       Impact factor: 3.490

4.  Rifampicin sensitivity of the components of DNA-dependent RNA polymerase.

Authors:  E di Mauro; L Synder; P Marino; A Lamberti; A Coppo; G P Tocchini-Valentini
Journal:  Nature       Date:  1969-05-10       Impact factor: 49.962

5.  Antimicrobial resistance of Vibrio parahaemolyticus and Vibrio alginolyticus strains isolated from farmed fish in Korea from 2005 through 2007.

Authors:  Eun-Gyoung Oh; Kwang-Tae Son; Hongsik Yu; Tae-Seek Lee; Hee-Jung Lee; Soonbum Shin; Ji-Young Kwon; Kunbawui Park; Jihoe Kim
Journal:  J Food Prot       Date:  2011-03       Impact factor: 2.077

6.  A new family of mobilizable suicide plasmids based on broad host range R388 plasmid (IncW) and RP4 plasmid (IncPalpha) conjugative machineries and their cognate Escherichia coli host strains.

Authors:  Gaëlle Demarre; Anne-Marie Guérout; Chiho Matsumoto-Mashimo; Dean A Rowe-Magnus; Philippe Marlière; Didier Mazel
Journal:  Res Microbiol       Date:  2005-03       Impact factor: 3.992

7.  Mutation to rifampicin resistance at the beginning of the RNA polymerase beta subunit gene in Escherichia coli.

Authors:  N A Lisitsyn; E D Sverdlov; E P Moiseyeva; O N Danilevskaya; V G Nikiforov
Journal:  Mol Gen Genet       Date:  1984

8.  Fitness Cost of Rifampin Resistance in Neisseria meningitidis: In Vitro Study of Mechanisms Associated with rpoB H553Y Mutation.

Authors:  Roberta Colicchio; Chiara Pagliuca; Gabiria Pastore; Annunziata Gaetana Cicatiello; Caterina Pagliarulo; Adelfia Talà; Elena Scaglione; Josè Camilla Sammartino; Cecilia Bucci; Pietro Alifano; Paola Salvatore
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

9.  Evolution of Escherichia coli rifampicin resistance in an antibiotic-free environment during thermal stress.

Authors:  Alejandra Rodríguez-Verdugo; Brandon S Gaut; Olivier Tenaillon
Journal:  BMC Evol Biol       Date:  2013-02-22       Impact factor: 3.260

Review 10.  The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin?

Authors:  Anastasia Koch; Valerie Mizrahi; Digby F Warner
Journal:  Emerg Microbes Infect       Date:  2014-03-12       Impact factor: 7.163

View more
  2 in total

1.  Microbial Musings - December 2020.

Authors:  Gavin H Thomas
Journal:  Microbiology (Reading)       Date:  2020-12       Impact factor: 2.777

2.  Antimicrobial Blue Light for Prevention and Treatment of Highly Invasive Vibrio vulnificus Burn Infection in Mice.

Authors:  Carolina Dos Anjos; Leon G Leanse; Xiaojing Liu; Hugo V Miranda; R Rox Anderson; Tianhong Dai
Journal:  Front Microbiol       Date:  2022-07-12       Impact factor: 6.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.